moxifloxacin has been researched along with amoxicillin in 88 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (amoxicillin) | Trials (amoxicillin) | Recent Studies (post-2010) (amoxicillin) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 10,915 | 2,661 | 3,467 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (2.27) | 18.2507 |
| 2000's | 39 (44.32) | 29.6817 |
| 2010's | 39 (44.32) | 24.3611 |
| 2020's | 8 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Duewelhenke, N; Eysel, P; Krut, O | 1 |
| Bryk, A; Kanervo-Nordström, A; Könönen, E; Niemi, P | 1 |
| Chang, CL; Jeong, J; Jeong, SH; Jung, HJ; Kim, HR; Kim, S; Lee, EY; Lee, JN; Shin, JH | 1 |
| Giamarellou, H; Kyroudi, A; Papalois, A; Pefanis, A; Skiadas, I; Triantafyllidi, H; Tsaganos, T | 1 |
| Calvet, L; Devine, R; Dubreuil, L; Jean-Pierre, H; Jumas-Bilak, E; Marchandin, H; Mercier, G; Morio, F | 1 |
| Desroches, MC; Grayo, S; Join-Lambert, O; Le Monnier, A | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Betriu, C; Culebras, E; Gómez, M; López, F; Picazo, JJ; Rodríguez-Avial, I | 1 |
| Dussurget, O; Fontanet, A; Grayo, S; Join-Lambert, O; Le Monnier, A; Lott-Desroches, MC; Respaud, R; Singlas, E | 1 |
| Hsueh, PR; Huang, YT; Liao, CH; Lin, HY; Liu, CY; Yen, LC | 1 |
| Cattoir, V; Nordmann, P; Poirel, L | 1 |
| Karlowsky, JA; Laing, NM; Zhanel, GG | 1 |
| Appelbaum, PC; Ednie, LM; Kosowska-Shick, K; McGhee, P | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Amaral, K; Dzink-Fox, J; Fischer, E; Goldovitz, J; Manni, K; Neckermann, G; Osborne, CS; Pecanka, R; Ryder, NS; Yu, D | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Cai, L; Gilbert, GL; Kong, F; Oftadeh, S; Xiao, M; Xu, X; Zhou, F | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Bajaksouzian, S; Biek, D; Critchley, IA; Good, CE; Jacobs, MR; Jones, RN; Sader, HS; Windau, AR | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Inagaki, H; Kitamura, T; Komoriya, S; Kuroyanagi, J; Miyauchi, RN; Nagamochi, M; Odagiri, T; Sugimoto, Y; Takahashi, H | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Devi, PB; Meda, N; Samala, G; Saxena, S; Sriram, D; Yogeeswari, P | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Appelbaum, PC; Jacobs, MR; Visalli, MA | 1 |
| Eliopoulos, GM; Souli, M; Wennersten, CB | 1 |
| Botzenhart, K; Dalhoff, A; Döring, G; Kaygin, H; Steinhuber, A; Worlitzsch, D | 1 |
| Arvis, P; Marel, M; Moita, J; Petitpretz, P; Urueta, J | 1 |
| Duprat-Lomon, I; Lamping, DL; Marquis, P; Marrel, A; Sagnier, PP; Schroter, S | 1 |
| Corris, P; Duprat-Lomon, I; Höffken, G; Kubin, R; Muir, JF; Sagnier, PP; Torres, A | 1 |
| de la Roza, C; Jardim, JR; Miravitlles, M; Obispo, E; Rico, G; Urueta, J; Wolff, M | 1 |
| Allegra, L; Huchon, G; Izquierdo, JL; Jones, P; Sagnier, PP; Schaberg, T; Wilson, R | 1 |
| De Vecchi, E; Drago, L; Gismondo, MR; Nicola, L; Tocalli, L | 1 |
| Cots, JM; Llor, C; Miravitlles, M; Molina, J; Naberan, K | 2 |
| Cammarota, G; Candelli, M; Cazzato, IA; Cremonini, F; Finizio, R; Gasbarrini, A; Gasbarrini, G; Nista, EC; Ojetti, V; Pignataro, G; Santoro, M; Zocco, MA | 1 |
| De Vecchi, E; Drago, L; Legnani, D; Nicola, L; Prenna, M; Ripa, S | 1 |
| Albers, C; Dalhoff, A; Döring, G; Korfmann, G; Künkele, F; Möller, JG; Ulrich, M | 1 |
| Cheon, JH; Jung, HC; Kim, JM; Kim, JS; Kim, N; Lee, DH; Song, IS | 1 |
| Alvarez Fernández, M; Diz Dios, P; Fernández Feijoo, J; Limeres Posse, J; Medina Henríquez, J; Tomás Carmona, I | 1 |
| Bélanger, M; LeCorn, DW; Progulske-Fox, A; Rojas, MF; Vertucci, FJ | 1 |
| Altintaş, E; Sezgin, O; Tellioğlu, B; Tombak, A; Uçbilek, E | 1 |
| Alvarez, M; Diz, P; Limeres, J; Potel, C; Tomás, I; Tomás, M; Velasco, D | 1 |
| Jung, HC; Kang, JM; Kim, JS; Kim, N; Kim, YR; Lee, DH; Park, YS; Song, IS | 1 |
| Decramer, M; Martin, M; Moore, L; Quilici, S; Simoens, S | 1 |
| Cakal, B; Kiliç, ZM; Köksal, AS; Kuran, S; Nadir, I; Ozin, YO; Sahin, B | 1 |
| Chhabra, MS; Mortensen, JE; Motley, WW | 1 |
| Hwang, TJ; Jung, HC; Kim, N; Lee, BH; Lee, DH; Nam, RH; Park, YS; Song, IS; Yoon, H | 1 |
| Amábile-Cuevas, CF; Arvis, P; Bogner, JR; Cruz-Alcázar, J; Hernández-Oliva, G; Reimnitz, P; Vick-Fragoso, R | 1 |
| Amitrano, M; Grossi, L; Manzoli, L; Marzio, L; Sacco, F; Spezzaferro, M | 1 |
| Ardila, CM; Granada, MI; Guzmán, IC | 1 |
| Hsueh, PR; Lee, PI; Yang, JC | 1 |
| Jung, HC; Kim, JY; Kim, N; Park, JH; Park, SY; Song, IS; Yoon, H | 1 |
| Al-Nawas, B; d'Hoedt, B; Karbach, J; Mouratidou, A | 1 |
| Baik, GH; Jung, HC; Kim, GH; Kim, HB; Kim, JM; Kim, JY; Kim, NY; Kim, SJ; Lee, DH; Nam, RH; Song, IS | 1 |
| Berning, M; Jebens, C; Knoth, H; Krasz, S; Kuhlisch, E; Laass, MW; Lehn, N; Madisch, A; Miehlke, S; Morgner, A; Neumeyer, M; Schneider-Brachert, W; Stolte, M; Vieth, M; Zekorn, C | 1 |
| Carbonnelle, S; De Bel, A; Dediste, A; Glupczynski, Y; Huang, TD; Jacobs, F; Jordens, P; Lismond, A; Schatt, P; Tulkens, PM; Van Bambeke, F; Verhaegen, J; Verschuren, F | 1 |
| Cellini, L; Ciccaglione, AF; Grossi, L; Marzio, L | 1 |
| Slavin, MA; Thursky, KA | 1 |
| Akan, H; Akova, M; Aoun, M; Calandra, T; de Bock, R; Drgona, L; Kern, WV; Marchetti, O; Paesmans, M; Viscoli, C | 1 |
| Jo, HJ; Kim, MS; Kim, N; Kim, SE; Lee, DH; Park, YS; Shin, CM | 1 |
| Al-Ahmad, A; Ameen, H; Anderson, AC; Hellwig, E; Karygianni, L; Pelz, K; Spitzmüller, B; Wittmer, A | 1 |
| Akdoğan, RA; Bedir, R; Copur, A; Rakici, H; Yilmaz, A | 1 |
| Jo, HJ; Kim, N; Lee, DH; Lee, ST; Lim, JH; Park, YS; Shin, CM; Song, IS | 1 |
| Cho, Y; Chung, KH; Hwang, JH; Jeong, SH; Jin, E; Kim, JW; Kim, N; Lee, DH; Seo, JY; Shin, CM | 1 |
| Almela, P; Angueira, T; Ariño, I; Barrio, J; Bermejo, F; Domínguez, JL; Domínguez-Muñoz, JE; Federico, A; Fernández, N; Fernandez-Bermejo, M; Ferrer-Barcelo, L; Gisbert, JP; Gomez, B; Gomez-Camarero, J; Gravina, AG; Lucendo, AJ; Marín, AC; Martin-Noguerol, E; Martorano, M; McNicholl, AG; Medina, E; Millastre, J; Miranda, A; Modolell, I; Molina-Infante, J; Ortuño, J; Perez-Aisa, Á; Perona, M; Rodríguez-Tellez, M; Romano, M | 1 |
| Akdogan, RA; Ayaz, T; Bedir, R; Rakici, H | 1 |
| Hwang, JJ; Kim, N; Lee, AR; Lee, DH; Park, YS; Shin, CM; Yoon, H | 1 |
| Gurgan, CA; Guzeldemir-Akcakanat, E | 1 |
| Choi, YJ; Kim, N; Kwon, YH; Lee, DH; Lee, JW; Lee, JY; Nam, RH; Suh, JH; Yoon, K | 1 |
| Cataldi, V; Cellini, L; Ciccaglione, AF; Di Bartolomeo, S; Di Campli, E; Di Giulio, M; Grossi, L; Marzio, L; Nostro, A | 1 |
| Kim, N; Lee, DH; Lee, ST; Lim, JH; Park, YS; Shin, CM; Song, IS | 1 |
| Jaeger, B; Pajkrt, D; Said, I; van de Beek, D; van Hest, RM; Wildenbeest, JG | 1 |
| Gisbert, JP; Marin, AC; McNicholl, AG; Nyssen, OP | 1 |
| Fattahi, G; Safarnejad, S; Shafahi Tilaki, S; Talebi Bezmin Abadi, A | 1 |
| Choi, YJ; Kang, JB; Kim, N; Kwon, S; Lee, DH; Park, YS; Shin, CM; Yoon, H | 1 |
| Morgando, A; Younes, R | 1 |
| Herath, SC; Maisey, S; Normansell, R; Poole, P | 1 |
| Heo, JJ; Jung, K; Kim, JH; Kim, SE; Moon, W; Park, MI; Park, SJ; Roh, JH | 1 |
| Ardila, CM; Bedoya-García, JA; Castañeda-Parra, LD; Flórez-Flórez, J; Guzmán, IC | 1 |
| Ardila, CM; Bedoya-García, JA; Hernández-Casas, C | 1 |
| Berjeaud, JM; Crapart, S; Crépin, A; Ecale, F; El Houari, A; Laparre, J; Ramnath, M; Rodier, MH | 1 |
| Areia, M; Barrio, J; Beglinger, C; Bordin, D; Boyanova, L; Bujanda, L; Buzas, GM; Bytzer, P; Caldas, M; Capelle, L; Castro-Fernandez, M; Doulberis, M; Fernandez-Salazar, L; Gasbarrini, A; Gisbert, JP; Goldis, A; Huguet, JM; Jonaitis, L; Jurecic, NB; Kunovský, L; Kupčinskas, J; Lamy, V; Lanas, A; Lasala, JP; Leja, M; Lerang, F; Lucendo, AJ; Marcos-Pinto, R; Marlicz, W; Megraud, F; Milivojevic, V; Molina-Infante, J; Morain, CO; Niv, Y; Nyssen, OP; Ortuño, J; Pérez Aísa, Á; Phull, P; Puig, I; Rodrigo, L; Rokkas, T; Sarsenbaeva, AS; Shvets, O; Simsek, I; Smith, S; Tepes, B; Tonkić, A; Vaira, D; Venerito, M; Vologzhanina, L; Voynovan, I | 1 |
| Choi, SI; Jang, JY; Kim, N; Lee, DH; Lee, JW; Nam, RH; Song, CH | 1 |
| Chu, N; Gu, Y; Luo, H; Wang, Q; Xiao, Y; Yang, J; Zhang, J | 1 |
| Bock, M; Bruun, NE; Bundgaard, H; Christensen, JJ; Christiansen, U; Elming, H; Fosbøl, EL; Fuursted, K; Gill, S; Helweg-Larsen, J; Høfsten, D; Høiby, N; Ihlemann, N; Iversen, K; Kristensen, JH; Køber, L; Lemming, L; Lerche, CJ; Moser, C; Nielsen, HL; Pedersen, CT; Povlsen, JA; Pries-Heje, MM; Rosenvinge, FS; Schultz, M; Theut, AM; Tønder, N; van Hasselt, JGC; Wang, H | 1 |
| Attin, T; Bensland, S; Eick, S; Karygianni, L; Kulik, EM; Thurnheer, T | 1 |
4 review(s) available for moxifloxacin and amoxicillin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Neonate with Mycoplasma hominis meningoencephalitis given moxifloxacin.
Topics: Acyclovir; Amoxicillin; Anti-Bacterial Agents; Antiviral Agents; Cefotaxime; Cerebrospinal Fluid; Female; Fever; Fluoroquinolones; Humans; Infant, Newborn; Meningoencephalitis; Moxifloxacin; Mycoplasma hominis; Polymerase Chain Reaction | 2016 |
Efficacy and Safety of Quinolone-Containing Rescue Therapies After the Failure of Non-Bismuth Quadruple Treatments for Helicobacter pylori Eradication: Systematic Review and Meta-Analysis.
Topics: Amoxicillin; Antacids; Bismuth; Clarithromycin; Drug Therapy, Combination; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Moxifloxacin; Proton Pump Inhibitors; Quinolones | 2017 |
Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD).
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Antibiotic Prophylaxis; Aza Compounds; Azithromycin; Clarithromycin; Clavulanic Acid; Disease Progression; Drug Administration Schedule; Erythromycin; Fluoroquinolones; Humans; Moxifloxacin; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolines; Randomized Controlled Trials as Topic; Roxithromycin; Trimethoprim, Sulfamethoxazole Drug Combination | 2018 |
26 trial(s) available for moxifloxacin and amoxicillin
| Article | Year |
|---|---|
Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults.
Topics: Administration, Oral; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents; Aza Compounds; Community-Acquired Infections; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Pneumonia, Pneumococcal; Quinolines; Treatment Outcome | 2001 |
The community-acquired pneumonia symptom questionnaire: a new, patient-based outcome measure to evaluate symptoms in patients with community-acquired pneumonia.
Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Aza Compounds; Clarithromycin; Community-Acquired Infections; Double-Blind Method; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Outcome Assessment, Health Care; Pneumonia, Bacterial; Psychometrics; Quality Assurance, Health Care; Quinolines; Surveys and Questionnaires | 2002 |
Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia.
Topics: Administration, Oral; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Clarithromycin; Community-Acquired Infections; Double-Blind Method; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Penicillins; Pneumonia; Quinolines | 2003 |
[A comparison of moxifloxacin and amoxicillin in the treatment of community-acquired pneumonia in Latin America: results of a multicenter clinical trial].
Topics: Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Community-Acquired Infections; Double-Blind Method; Female; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Latin America; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Prospective Studies; Quinolines; Streptococcus pneumoniae; Treatment Outcome | 2003 |
Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis.
Topics: Acute Disease; Aged; Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Bronchitis, Chronic; Cefuroxime; Clarithromycin; Double-Blind Method; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Quinolines | 2004 |
Moxifloxacin-based strategies for first-line treatment of Helicobacter pylori infection.
Topics: Adult; Amoxicillin; Aza Compounds; Drug Therapy, Combination; Dyspepsia; Esomeprazole; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Moxifloxacin; Patient Compliance; Prospective Studies; Quinolines; Tinidazole; Treatment Outcome | 2005 |
Variables associated with recovery from acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease.
Topics: Acute Disease; Adrenergic beta-Agonists; Adult; Aged; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Aza Compounds; Bronchitis, Chronic; Clarithromycin; Drug Therapy, Combination; Epidemiologic Methods; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Oxygen Inhalation Therapy; Prognosis; Pulmonary Disease, Chronic Obstructive; Quinolines; Treatment Outcome | 2005 |
Efficacy of moxifloxacin-based triple therapy as second-line treatment for Helicobacter pylori infection.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Esomeprazole; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Moxifloxacin; Organometallic Compounds; Patient Compliance; Quinolines; Tetracycline; Treatment Outcome | 2006 |
Comparative efficacies of amoxicillin, clindamycin, and moxifloxacin in prevention of bacteremia following dental extractions.
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Antibiotic Prophylaxis; Aza Compounds; Bacteremia; Clindamycin; Double-Blind Method; Female; Fluoroquinolones; Humans; Male; Moxifloxacin; Prospective Studies; Quinolines; Streptococcal Infections; Streptococcus; Tooth Extraction | 2006 |
Low efficacy rate of moxifloxacin-containing Helicobacter pylori eradication treatment: in an observational study in a Turkish population.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Aza Compounds; Drug Therapy, Combination; Dyspepsia; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Moxifloxacin; Pantoprazole; Peptic Ulcer; Pilot Projects; Quinolines; Treatment Outcome; Turkey | 2007 |
Second-line treatment for Helicobacter pylori infection: 10-day moxifloxacin-based triple therapy versus 2-week quadruple therapy.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Moxifloxacin; Organometallic Compounds; Patient Compliance; Quinolines; Tetracycline | 2007 |
Moxifloxacine plus amoxicillin and ranitidine bismuth citrate or esomeprazole triple therapies for Helicobacter pylori infection.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Aza Compounds; Bismuth; Breath Tests; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Fluoroquinolones; Helicobacter Infections; Humans; Male; Middle Aged; Moxifloxacin; Pilot Projects; Prospective Studies; Quinolines; Ranitidine; Treatment Outcome; Young Adult | 2008 |
Efficacy and safety of sequential intravenous/oral moxifloxacin vs intravenous/oral amoxicillin/clavulanate for complicated skin and skin structure infections.
Topics: Administration, Oral; Adult; Aged; Amoxicillin; Aza Compounds; Clavulanic Acid; Female; Fluoroquinolones; Humans; Injections, Intravenous; Male; Middle Aged; Moxifloxacin; Prospective Studies; Quinolines; Skin Diseases, Bacterial; Treatment Outcome | 2009 |
Efficacy of four different moxifloxacin-based triple therapies for first-line H. pylori treatment.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aza Compounds; Breath Tests; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Moxifloxacin; Quinolines; Urea; Young Adult | 2010 |
Effects of multistrain probiotic-containing yogurt on second-line triple therapy for Helicobacter pylori infection.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Bifidobacterium; Breath Tests; Chi-Square Distribution; Drug Therapy, Combination; Esomeprazole; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Lacticaseibacillus casei; Lactobacillus acidophilus; Male; Middle Aged; Moxifloxacin; Probiotics; Prospective Studies; Proton Pump Inhibitors; Quinolines; Republic of Korea; Streptococcus thermophilus; Time Factors; Treatment Outcome; Urease; Yogurt | 2011 |
Randomized trial on 14 versus 7 days of esomeprazole, moxifloxacin, and amoxicillin for second-line or rescue treatment of Helicobacter pylori infection.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aza Compounds; Breath Tests; Drug Therapy, Combination; Esomeprazole; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Quinolines; Salvage Therapy; Time Factors; Treatment Outcome; Urea; White People | 2011 |
Quadruple therapy with moxifloxacin and bismuth for first-line treatment of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Infective Agents; Aza Compounds; Drug Therapy, Combination; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Moxifloxacin; Organometallic Compounds; Pantoprazole; Proton Pump Inhibitors; Quinolines; Treatment Outcome | 2012 |
Oral antibiotics for fever in low-risk neutropenic patients with cancer: a double-blind, randomized, multicenter trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus amoxicillin/clavulanic acid combination therapy--EORTC infectiou
Topics: Administration, Oral; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Clavulanic Acid; Double-Blind Method; Drug Combinations; Female; Fever; Fluoroquinolones; Humans; Injections, Intravenous; Male; Middle Aged; Moxifloxacin; Neoplasms; Neutropenia; Quinolines; Risk Factors; Treatment Outcome | 2013 |
Long-term follow up Helicobacter Pylori reinfection rate after second-line treatment: bismuth-containing quadruple therapy versus moxifloxacin-based triple therapy.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aza Compounds; Breath Tests; Disease-Free Survival; Drug Therapy, Combination; Esomeprazole; Female; Fluoroquinolones; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Kaplan-Meier Estimate; Longitudinal Studies; Male; Metronidazole; Middle Aged; Moxifloxacin; Organometallic Compounds; Peptic Ulcer; Quinolines; Recurrence; Stomach Neoplasms; Tetracycline; Treatment Outcome | 2013 |
Comparison of standard triple therapy, sequential therapy and moxifloxacin-based triple therapy for Helicobacter pylori infection: Patients' compliance and bacterial eradication rates.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Medication Adherence; Metronidazole; Middle Aged; Moxifloxacin; Proton Pump Inhibitors; Treatment Outcome; Young Adult | 2014 |
Comparison of levofloxacin- and moxifloxacin-based triple therapies with standard treatment in eradication of Helicobacter pylori as first-line therapy.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Levofloxacin; Male; Middle Aged; Moxifloxacin; Proton Pump Inhibitors; Treatment Outcome; Young Adult | 2014 |
Systemic moxifloxacin vs amoxicillin/metronidazole adjunct to non-surgical treatment in generalized aggressive periodontitis.
Topics: Adult; Aggressive Periodontitis; Amoxicillin; Anti-Infective Agents; Drug Therapy, Combination; Female; Fluoroquinolones; Follow-Up Studies; Humans; Male; Metronidazole; Moxifloxacin; Young Adult | 2015 |
Comparison of the efficacy of culture-based tailored therapy for Helicobacter pylori eradication with that of the traditional second-line rescue therapy in Korean patients: a prospective single tertiary center study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combination; Esomeprazole; Female; Fluoroquinolones; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Organometallic Compounds; Prospective Studies; Proton Pump Inhibitors; Republic of Korea; Tertiary Care Centers; Tetracycline; Young Adult | 2016 |
Moxifloxacin versus amoxicillin plus metronidazole as adjunctive therapy for generalized aggressive periodontitis: a pilot randomized controlled clinical trial.
Topics: Aggressive Periodontitis; Amoxicillin; Anti-Bacterial Agents; Dental Scaling; Humans; Metronidazole; Moxifloxacin; Periodontal Attachment Loss; Periodontal Pocket; Porphyromonas gingivalis; Treatment Outcome | 2020 |
Effects on clinical outcomes of adjunctive moxifloxacin versus amoxicillin plus metronidazole in periodontitis patients harboring Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis, and Tannerella forsythia: exploratory analyses from a clinic
Topics: Adult; Aggregatibacter actinomycetemcomitans; Amoxicillin; Anti-Bacterial Agents; Humans; Metronidazole; Moxifloxacin; Periodontal Attachment Loss; Periodontal Pocket; Periodontitis; Porphyromonas gingivalis; Tannerella; Tannerella forsythia | 2021 |
Prevalence and trends of multiple antimicrobial resistance of Helicobacter pylori in one tertiary hospital for 20 years in Korea.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Microbial Sensitivity Tests; Moxifloxacin; Prevalence; Republic of Korea; Tertiary Care Centers | 2023 |
58 other study(ies) available for moxifloxacin and amoxicillin
| Article | Year |
|---|---|
Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines.
Topics: Acetamides; Aminoglycosides; Anti-Bacterial Agents; Antimycin A; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cells, Cultured; Chloramphenicol; Clindamycin; Dose-Response Relationship, Drug; Fluoroquinolones; Glycolysis; HeLa Cells; Humans; Lactic Acid; Linezolid; Macrolides; Mitochondria; Osteoblasts; Oxazolidinones; Rotenone; Tetracyclines; Time Factors | 2007 |
Antimicrobial susceptibilities of Peptostreptococcus anaerobius and the newly described Peptostreptococcus stomatis isolated from various human sources.
Topics: Anaerobiosis; Anti-Bacterial Agents; Bacteremia; Gram-Positive Bacterial Infections; Humans; Microbial Sensitivity Tests; Peptostreptococcus; Species Specificity | 2007 |
Prevalence, characteristics, and molecular epidemiology of macrolide and fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae at five tertiary-care hospitals in Korea.
Topics: Anti-Bacterial Agents; Community-Acquired Infections; DNA, Bacterial; Drug Resistance, Bacterial; Erythromycin; Fluoroquinolones; Genes, Bacterial; Hospitals; Humans; Korea; Levofloxacin; Macrolides; Microbial Sensitivity Tests; Molecular Epidemiology; Mutation; Ofloxacin; Pneumococcal Infections; Polymerase Chain Reaction; Prevalence; Reserpine; Respiratory Tract Infections; Retrospective Studies; Streptococcus pneumoniae | 2007 |
Dexamethasone as adjuvant therapy to moxifloxacin attenuates valve destruction in experimental aortic valve endocarditis due to Staphylococcus aureus.
Topics: Adjuvants, Immunologic; Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Aortic Valve; Aza Compounds; Dexamethasone; Disease Models, Animal; Echocardiography; Endocarditis, Bacterial; Fluoroquinolones; Humans; Methicillin; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Rabbits; Staphylococcal Infections; Staphylococcus aureus; Treatment Outcome | 2007 |
Antimicrobial susceptibilities and clinical sources of Dialister species.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Species Specificity; Veillonellaceae | 2007 |
Comparison of the in vitro efficacies of moxifloxacin and amoxicillin against Listeria monocytogenes.
Topics: Amoxicillin; Animals; Aza Compounds; Cells, Cultured; Fluoroquinolones; Listeria monocytogenes; Macrophages; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Moxifloxacin; Quinolines | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
Topics: Anti-Bacterial Agents; Bacteroides; Bacteroides fragilis; Bacteroides Infections; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tests; Spain; Species Specificity; Time Factors | 2008 |
Rapid eradication of Listeria monocytogenes by moxifloxacin in a murine model of central nervous system listeriosis.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Brain; Brain Diseases; Central Nervous System Bacterial Infections; Disease Models, Animal; Fluoroquinolones; Listeria monocytogenes; Listeriosis; Mice; Moxifloxacin; Quinolines; Time Factors; Treatment Outcome | 2008 |
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; Bacteroides fragilis; Bacteroides Infections; Blood; Carbapenems; Cross Infection; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Taiwan | 2008 |
Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
Topics: Aged; Base Sequence; DNA Primers; DNA, Bacterial; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Female; Fluoroquinolones; France; Genes, Bacterial; Humans; Models, Genetic; Molecular Sequence Data; Plasmids | 2008 |
In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile.
Topics: Anti-Bacterial Agents; Bacterial Toxins; Clostridioides difficile; Cross Infection; Enterocolitis, Pseudomembranous; Glycosides; Humans; In Vitro Techniques; Microbial Sensitivity Tests | 2008 |
Comparative antipneumococcal activities of sulopenem and other drugs.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Lactams; Microbial Sensitivity Tests; Penicillin-Binding Proteins; Streptococcus pneumoniae | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models.
Topics: Acetamides; Amidohydrolases; Animals; Anti-Infective Agents; Female; Linezolid; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Molecular Structure; Oxazolidinones; Peptides; Pneumonia; Staphylococcus aureus; Streptococcus pneumoniae; Thigh | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Distribution of serotypes, genotypes, and resistance determinants among macrolide-resistant Streptococcus pneumoniae isolates.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Child, Preschool; DNA Transposable Elements; Drug Resistance, Bacterial; Erythromycin; Genotype; Humans; Macrolides; Microbial Sensitivity Tests; New South Wales; Pneumococcal Infections; Serotyping; Streptococcus pneumoniae | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Communicable Diseases, Emerging; Drug Resistance, Multiple, Bacterial; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Pneumococcal Infections; Serotyping; Streptococcus pneumoniae; United States | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Design, synthesis, and biological evaluations of novel 7-[7-amino-7-methyl-5-azaspiro[2.4]heptan-5-yl]-8-methoxyquinolines with potent antibacterial activity against respiratory pathogens.
Topics: Animals; Anti-Bacterial Agents; Drug Design; Fluoroquinolones; Haemophilus influenzae; Male; Mice; Microbial Sensitivity Tests; Quinolones; Rats; Respiratory Tract Infections; Spiro Compounds; Staphylococcus aureus; Streptococcus pneumoniae | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Design, synthesis and biological evaluation of imidazo[2,1-b]thiazole and benzo[d]imidazo[2,1-b]thiazole derivatives as Mycobacterium tuberculosis pantothenate synthetase inhibitors.
Topics: Animals; Anti-Bacterial Agents; Dose-Response Relationship, Drug; Drug Design; Enzyme Inhibitors; Imidazoles; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Peptide Synthases; Structure-Activity Relationship; Thiazoles; Zebrafish | 2016 |
Antipneumococcal activity of BAY 12-8039, a new quinolone, compared with activities of three other quinolones and four oral beta-lactams.
Topics: Administration, Oral; Amoxicillin; Ampicillin; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Cefpodoxime; Ceftizoxime; Cefuroxime; Fluoroquinolones; Microbial Sensitivity Tests; Moxifloxacin; Penicillin Resistance; Quinolines; Quinolones; Streptococcus pneumoniae | 1997 |
In vitro activity of BAY 12-8039, a new fluoroquinolone, against species representative of respiratory tract pathogens.
Topics: Amoxicillin; Anti-Infective Agents; Aza Compounds; Cefuroxime; Clavulanic Acid; Erythromycin; Fluoroquinolones; Methicillin Resistance; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Penicillin Resistance; Quinolines; Quinolones; Staphylococcus aureus; Streptococcus; Streptococcus pneumoniae; Streptococcus pyogenes | 1998 |
Effects of amoxicillin, gentamicin, and moxifloxacin on the hemolytic activity of Staphylococcus aureus in vitro and in vivo.
Topics: Amoxicillin; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Blotting, Northern; Blotting, Western; Coloring Agents; Congo Red; Cystic Fibrosis; Fluoroquinolones; Gentamicins; Granuloma; Hemolysis; HLA Antigens; Humans; Leukocyte Elastase; Male; Moxifloxacin; Penicillins; Quinolines; Rats; Rats, Wistar; Staphylococcal Infections; Staphylococcal Protein A; Staphylococcus aureus | 2001 |
[Acute exacerbated chronic bronchitis. Antibiotics in comparison].
Topics: Acute Disease; Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Bronchitis, Chronic; Cefuroxime; Clarithromycin; Fluoroquinolones; Humans; Moxifloxacin; Quinolines; Randomized Controlled Trials as Topic; Smoking; Time Factors | 2003 |
Effect of moxifloxacin on bacterial pathogenicity factors in comparison with amoxicillin, clarithromycin and ceftriaxone.
Topics: Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Ceftriaxone; Clarithromycin; Dose-Response Relationship, Drug; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests; Moxifloxacin; Quinolines | 2004 |
Economic evaluation of the antibiotic treatment of exacerbations of chronic bronchitis and COPD in primary care.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Bronchitis, Chronic; Clarithromycin; Clavulanic Acid; Cost of Illness; Cost-Benefit Analysis; Data Collection; Female; Fluoroquinolones; Humans; Male; Moxifloxacin; Pilot Projects; Pulmonary Disease, Chronic Obstructive; Quinolines; Treatment Outcome | 2004 |
In vitro selection of resistance to clarithromycin in Streptococcus pneumoniae clinical isolates.
Topics: Amoxicillin; Aza Compounds; Azithromycin; Clarithromycin; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Sampling Studies; Sensitivity and Specificity; Streptococcus pneumoniae | 2005 |
Moxifloxacin and azithromycin but not amoxicillin protect human respiratory epithelial cells against streptococcus pneumoniae in vitro when administered up to 6 hours after challenge.
Topics: Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Azithromycin; Epithelial Cells; Fluoroquinolones; Humans; Moxifloxacin; Quinolines; Streptococcus pneumoniae | 2005 |
In vitro activity of amoxicillin, clindamycin, doxycycline, metronidazole, and moxifloxacin against oral Actinomyces.
Topics: Actinomyces; Actinomycosis; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Clindamycin; Doxycycline; Fluoroquinolones; Humans; Metronidazole; Moxifloxacin; Periapical Periodontitis; Quinolines | 2007 |
Susceptibility of oral obligate anaerobes to telithromycin, moxifloxacin and a number of commonly used antibacterials.
Topics: Adult; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Azithromycin; Blood; Clindamycin; Culture Media; Drug Resistance, Bacterial; Fluoroquinolones; Gram-Negative Anaerobic Bacteria; Hemin; Humans; Ketolides; Metronidazole; Microbial Sensitivity Tests; Moxifloxacin; Penicillin Resistance; Periodontitis; Quinolines; Saliva; Vitamin K | 2007 |
A cost-effectiveness analysis of antimicrobial treatment of community-acquired pneumonia taking into account resistance in Belgium.
Topics: Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Belgium; Cefuroxime; Clarithromycin; Community-Acquired Infections; Cost-Benefit Analysis; Decision Support Techniques; Drug Costs; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Humans; Moxifloxacin; Pneumonia, Bacterial; Quinolines | 2008 |
Eikenella corrodens as a causative agent for neonatal conjunctivitis.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Clavulanic Acid; Conjunctivitis; Drug Administration Schedule; Drug Therapy, Combination; Eikenella corrodens; Female; Fluoroquinolones; Gram-Negative Bacterial Infections; Humans; Infant; Moxifloxacin; Ophthalmic Solutions; Quinolines; Treatment Outcome | 2008 |
Moxifloxacin-containing triple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Drug Resistance, Bacterial; Drug Resistance, Microbial; Drug Therapy, Combination; Esomeprazole; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Moxifloxacin; Prospective Studies; Quinolines; Treatment Outcome | 2009 |
Antibiotic resistance of subgingival species in chronic periodontitis patients.
Topics: Adult; Aged; Aggregatibacter actinomycetemcomitans; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Ampicillin Resistance; Anti-Infective Agents; Aza Compounds; Bacteriological Techniques; beta-Lactam Resistance; Chronic Periodontitis; Clindamycin; Colombia; Dental Plaque; Drug Resistance, Bacterial; Female; Fluoroquinolones; Fusobacterium nucleatum; Gingival Hemorrhage; Humans; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Periodontal Attachment Loss; Periodontal Pocket; Porphyromonas gingivalis; Prevotella; Quinolines | 2010 |
In vitro activity of nemonoxacin, tigecycline, and other antimicrobial agents against Helicobacter pylori isolates in Taiwan, 1998-2007.
Topics: Amino Acid Substitution; Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Clarithromycin; DNA Gyrase; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gemifloxacin; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Microbial Sensitivity Tests; Minocycline; Moxifloxacin; Mutation; Naphthyridines; Ofloxacin; Quinolines; Quinolones; Sequence Analysis, Protein; Taiwan; Tetracyclines; Tigecycline | 2010 |
Antibiotic susceptibility of cocultures in polymicrobial infections such as peri-implantitis or periodontitis: an in vitro model.
Topics: Acetamides; Actinobacillus Infections; Aggregatibacter actinomycetemcomitans; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Ampicillin; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Azithromycin; Capnocytophaga; Coculture Techniques; Coinfection; Drug Resistance, Bacterial; Fluoroquinolones; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Linezolid; Metronidazole; Microbial Interactions; Minocycline; Moxifloxacin; Oxazolidinones; Penicillin G; Peptostreptococcus; Peri-Implantitis; Periodontitis; Quinolines; Sulbactam | 2011 |
[Regional difference of antibiotic resistance of helicobacter pylori strains in Korea].
Topics: Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Azithromycin; Ciprofloxacin; Clarithromycin; Drug Resistance, Bacterial; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines; Republic of Korea; Tetracycline | 2011 |
Antimicrobial susceptibility of Streptococcus pneumoniae isolates from vaccinated and non-vaccinated patients with a clinically confirmed diagnosis of community-acquired pneumonia in Belgium.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Belgium; beta-Lactams; Child; Child, Preschool; Clarithromycin; Community-Acquired Infections; Comorbidity; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Pneumonia, Pneumococcal; Quinolines; Streptococcus pneumoniae; Vaccination; Young Adult | 2012 |
Outpatient therapy for fever and neutropenia is safe but implementation is the key.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Female; Fever; Fluoroquinolones; Humans; Male; Moxifloxacin; Neoplasms; Neutropenia; Quinolines | 2013 |
Antibiotic resistance and capacity for biofilm formation of different bacteria isolated from endodontic infections associated with root-filled teeth.
Topics: Actinomyces; Actinomyces viscosus; Amoxicillin; Anti-Bacterial Agents; Biofilms; Ciprofloxacin; Clindamycin; Dental Pulp Diseases; Doxycycline; Drug Resistance, Bacterial; Enterococcus faecalis; Fluoroquinolones; Fosfomycin; Gentamicins; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Limosilactobacillus fermentum; Moxifloxacin; Penicillin G; Penicillin Resistance; Prevotella; Propionibacterium; Rifampin; Streptococcus mutans; Tetracycline Resistance; Tooth, Nonvital; Vancomycin Resistance | 2014 |
Efficacy of 7-Day and 14-Day Bismuth-Containing Quadruple Therapy and 7-Day and 14-Day Moxifloxacin-Based Triple Therapy as Second-Line Eradication for Helicobacter pylori Infection.
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Infective Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Male; Metronidazole; Middle Aged; Moxifloxacin; Proton Pump Inhibitors; Retrospective Studies; Tetracycline; Treatment Outcome | 2015 |
The efficacy of moxifloxacin-containing triple therapy after standard triple, sequential, or concomitant therapy failure for Helicobacter pylori eradication in Korea.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Cohort Studies; Drug Therapy, Combination; Female; Fluoroquinolones; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Moxifloxacin; Organometallic Compounds; Peptic Ulcer; Rabeprazole; Republic of Korea; Retrospective Studies; Salvage Therapy; Stomach; Tetracycline; Treatment Failure; Treatment Outcome; Urea | 2014 |
Two-week, high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatments.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Cohort Studies; Drug Therapy, Combination; Esomeprazole; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Moxifloxacin; Prospective Studies; Proton Pump Inhibitors; Retreatment; Treatment Failure; Treatment Outcome; Urea | 2015 |
Efficacy of 14-d vs 7-d moxifloxacin-based triple regimens for second-line Helicobacter pylori eradication.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Male; Medication Adherence; Middle Aged; Moxifloxacin; Proton Pump Inhibitors; Rabeprazole; Republic of Korea; Retrospective Studies; Time Factors; Treatment Outcome; Young Adult | 2015 |
In vitro antimicrobial susceptibility of Helicobacter pylori to nine antibiotics currently used in Central Italy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Ampicillin; Anti-Bacterial Agents; Child; Ciprofloxacin; Clarithromycin; Drug Resistance, Multiple, Bacterial; Dyspepsia; Female; Fluoroquinolones; Gastric Fundus; Helicobacter Infections; Helicobacter pylori; Humans; Italy; Levofloxacin; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Pyloric Antrum; Rifabutin; Tetracycline; Young Adult | 2016 |
Moxifloxacin-containing triple therapy after non-bismuth quadruple therapy failure for Helicobacter pylori infection.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Bacterial Load; Breath Tests; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Male; Middle Aged; Moxifloxacin; Proton Pump Inhibitors; Rabeprazole; Retreatment; Retrospective Studies; Time Factors; Treatment Failure | 2015 |
Moxifloxacin, but not Metronidazole can be used in therapeutic regimens against Helicobacter pylori.
Topics: Amoxicillin; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Moxifloxacin | 2017 |
[The Efficacy of Moxifloxacin-containing Triple Therapy after Hybrid Therapy Failure in
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Moxifloxacin; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Topoisomerase II Inhibitors; Treatment Failure; Treatment Outcome | 2017 |
Comment on Helicobacter pylori eradication using metronidazole.
Topics: Amoxicillin; Bismuth; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Moxifloxacin | 2018 |
Effect of 7-day Bismuth Quadruple Therapy versus 14-day Moxifloxacin Triple Therapy for Second-line
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Humans; Male; Metronidazole; Middle Aged; Moxifloxacin; Proton Pump Inhibitors; Retrospective Studies; Treatment Outcome | 2019 |
In vitro sensitivity of 30 anaerobic bacterial strains of the human intestinal core microbiota to antibiotics: Culture and LC-MS/MS approaches.
Topics: Amoxicillin; Anti-Bacterial Agents; Chromatography, Liquid; Gastrointestinal Microbiome; Humans; Mass Screening; Metronidazole; Microbial Sensitivity Tests; Moxifloxacin; Sulfamethoxazole; Tandem Mass Spectrometry | 2021 |
Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg).
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Moxifloxacin; Penicillins; Prospective Studies; Proton Pump Inhibitors; Quinolones; Registries; Tetracycline | 2022 |
Antimicrobial Resistance of Helicobacter Pylori Among Low-resource Chinese Minorities.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; China; Cross-Sectional Studies; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; East Asian People; Female; Gentamicins; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Metronidazole; Moxifloxacin; Rifampin | 2023 |
Attainment of Target Antibiotic Levels by Oral Treatment of Left-Sided Infective Endocarditis: A POET Substudy.
Topics: Amoxicillin; Anti-Bacterial Agents; Dicloxacillin; Endocarditis; Endocarditis, Bacterial; Humans; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Rifampin | 2023 |
Antibiotic Resistance among Fusobacterium, Capnocytophaga, and Leptotrichia Species of the Oral Cavity.
Topics: Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Infective Agents; Capnocytophaga; Ciprofloxacin; Clindamycin; Doxycycline; Drug Resistance, Bacterial; Fusobacterium; Humans; Leptothrix; Leptotrichia; Metronidazole; Microbial Sensitivity Tests; Moxifloxacin; Periodontal Diseases | 2023 |